LTRN - Lantern Pharma

-

$undefined

N/A

(N/A)

Lantern Pharma NasdaqCM:LTRN Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Location: 1920 McKinney Avenue, Dallas, TX, 75201, United States | Website: https://www.lanternpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

17.86M

Cash

24.01M

Avg Qtr Burn

-4.453M

Short % of Float

3.17%

Insider Ownership

14.72%

Institutional Own.

22.74%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
LP-300 Details
Non-small cell lung carcinoma, Cancer

Phase 2

Data readout

LP-100 (Irofulven) Details
Cancer, Castration-resistant prostate cancer

Phase 2

Update

LP-184 Details
Triple Negative Breast Cancer

Phase 1/2

Data readout

LP-184 Details
Non-small cell lung carcinoma

Phase 1/2

Initiation

LP-284 Details
Cancer, Non-Hodgkin lymphoma, Mantle cell lymphoma, High-grade Glioma

Phase 1

Data readout

LP-184 Details
Brain tumors (Pediatrics)

Phase 1

Initiation

LP-184 Details
Cancer, Solid tumor/s, Central nervous system illness

Phase 1a

Data readout